Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation

NCT07556068 · tracked via the Priya Life Science China tracker
Phase
Observational
Started
2026-04-20
Last updated
2026-05-06

Condition(s) studied

Acute Ischemic StrokeCerebral Autoregulation

Investigational drug(s) / intervention(s)

diagnostic accuracy study

diagnostic accuracy study: Cerebral autoregulation is assessed intraoperatively during thrombectomy using near-infrared spectroscopy (NIRS)-derived cerebral oxygen saturation combined with continuous noninvasive or invasive arterial blood pressure monitoring. The correlation between cerebral oxygen saturation and arterial blood pressure is analyzed to quantify cerebral autoregulation status. This monitoring is performed as part of routine clinical care and does not constitute an additional research intervention.

Study summary

This multicenter, prospective, observational diagnostic accuracy study enrolls patients undergoing thrombectomy with intraoperative cerebral autoregulation monitoring and follows them up at predefined time points up to 90 days post-enrollment. The study aims to determine whether impaired cerebral autoregulation during thrombectomy can serve as an ultra-early biomarker for predicting futile recanalization in patients with acute ischemic stroke.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age ≥ 18 2. Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (intracranial segment of the internal carotid artery, middle cerebral artery M1 segment) demonstrated with CTA/MRA/DSA. 3. NIHSS score ≥ 6 obtained prior to endovascular treatment. 4. Modified Rankin Scale ≤ 1 prior to qualifying stroke. 5. Acute ischemic stroke, undergone endovascular treatment within 24 hours of onset (time of stroke is the last known normal for wake-up stroke or with unknown onset time).with reaching the goal of mTICI grade 2b-3 6. For patients with symptom onset within 6 hours: ASPECTS ≥ 3; for patients with symptom onset between 6 and 24 hours: age ≤ 80 years and ASPECTS ≥ 3. 7. Patient/Legally Authorized Representative has signed the Informed Consent Form. Exclusion Criteria: 1. Baseline CT/MRI confirms the presence of multiple vascular territory acute strokes. 2. Baseline CT/MRI confirms the presence of arterial dissection. 3. Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy. 4. Known allergies or intolerances to antiplatelet agents, anticoagulation drugs, iodinated contrast and/or anesthetics. 5. Severe infection (e.g. sepsis) or multiple organ failure. 6. Known hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency; oral anticoagulant therapy with INR \> 3; or use of a factor Xa inhibitor within the preceding 48 hours with an abnormal aPTT. 7. Baseline platelet count \< 50 × 10\^9/L. 8. Blood glucose concentration\<50 mg/dL (2.7 mmol/L) or \>400 mg/dL (22.2 mmol/L). 9. Refractory hypertension that is difficult to control by medication (Defined as persistent systolic blood pressure\>185 mmHg or diastolic blood pressure\>110 mmHg). 10. Severe cardiomyopathy with heart failure (LVEF ≤ 30% or NYHA class IV), acute myocardial infarction, or unstable angina. 11. Untreated moderate or severe coronary artery stenosis, or previous coronary artery bypass surgery. 12. Current hemodialysis or peritoneal dialysis; known severe renal insufficiency with estimated glomerular filtration rate \< 30 mL/min or serum creatinine \> 220 μmol/L (2.5 mg/dL). 13. Known intracranial aneurysm, and cerebral arteriovenous malformation. 14. Malignant brain tumor or CNS infection. 15. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness) 16. Female who is pregnant or lactating at time of admission. 17. Anticipated life expectancy \< 6 months. 18. Current participation in another investigational drug or device study. 19. local skin damage or other conditions that cannot cooperate with electrode sticking. 20. severe agitation or other conditions affecting data collection.

Primary outcome measure(s)

  • The sensitivity, specificity and area under the receiver operating characteristic curve for percentage of Modified Rankin scale 0-2 — Month 3
    "Futile recanalization" is defined as a poor neurological prognosis (90-day Modified Rankin scale \> 2) in patients with acute large vessel occlusion ischemic stroke who have achieved good recanalization grade (mTICI≥2b) after endovascular treatment. The sensitivity, specificity and area under the receiver operating characteristic curve of cerebral autoregulation coefficient in predicting the percentage of mRS scale 0-2 (Modified Rankin scale \[ranging from 0 (normal) to 6 (death) were calculated.

Trial sites (4)

FacilityCityRegionStatus
Beijing Shijitan Hospital, Capital Medical University Beijing Beijing Municipality Recruiting
The First Affiliated Hospital of Harbin Medical University Harbin Heilongjiang Recruiting
Dalian Municipal Central Hospital Dalian Liaoning Not Yet Recruiting
Weifang People's Hospital Affiliated to Weifang Medical University Weifang Shandong Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07556068 on ClinicalTrials.gov ↗ ← All trials in China